Register. Neurology 2008;71(4):272-276. OBJECTIVES: Topiramate (Topamax ) is licensed to be used, either in monotherapy or as adjunctive treatment, for generalized tonic-clonic seizures or partial seizures with or without secondary generalization and for prevention of migraine. The safety of topiramate in human pregnancy is largely unknown. Here we report on our experience of pregnancies exposed to topiramate. METHODS: This study is part of a prospective, observational registration and follow-up study.
COMMENTARY
W omen of childbearing potential taking antiepileptic drugs (AEDs) are understandably concerned that AEDs will induce birth defects. The first question for expectant mothers is whether it is better to risk the ill effects of having a seizure off medications or the teratogenic effects of AEDs. It is commonly held that seizures during pregnancy induce fetal problems. There are case reports of fetal intracranial hemorrhage and fetal heart rate changes from convulsive seizures, although other observations have suggested few problems induced by nonconvulsive seizures (1) . Of course, the risk of status epilepticus occurring would be increased for a woman who chose to stop AEDs during pregnancy, and status epilepticus has a high mortality rate for the baby and mother. However, the actual frequency of seizure-induced harm during pregnancy is unknown. Nevertheless, seizures are preventable and the teratogenic risk of AEDs is apparently relatively low. Therefore, the prevailing practice is to continue AEDs during pregnancy at the lowest possible dose and with the fewest drugs, preferably monotherapy. AEDs should be withdrawn if they are not needed, and this issue should be reviewed before pregnancy.
The conclusion that a pregnant woman should remain on an AED is usually reached easily. A more common concern is the risk of teratogenicity conferred by the AED. There are no prospective controlled trials of AEDs in pregnant women for obvious ethical and logistical reasons; therefore, case series of pregnant women are the basis for assessment. The teratogenic risk of AEDs is seemingly low. Because large numbers of pregnant women with epilepsy on AEDs must be examined in order to find enough cases of major congenital malformations (MCMs) to calculate the teratogenic risk with any degree of certainty, large pregnancy registries have been the answer to this problem. The results, methodology, and limitations of these registries were reviewed in a recent consensus statement (1). Modern registries have been well designed to minimize bias, particularly with regard to selection, by enrolling women before the outcome of their pregnancy is known, then obtaining follow-up data to determine the outcome of the pregnancy.
Hunt et al. report the MCM rate for topiramate from the United Kingdom (UK) pregnancy registry. The MCM rate for topiramate was 4.8% for 70 monotherapy exposures and 11.2% for 108 polytherapy exposures. It is notable that 2.2% of topiramate treated patients had oral clefts; however, the confidence intervals are large so that the exact frequency is difficult to determine. The confidence intervals even include 1.0, raising the possibility that any increase risk calculated could be due merely This rate of 9.8% was not statistically different from the rate of 3.4% for 206 controls, obtained from women who had contacted their local teratogenicity information service. Interestingly, the investigators identified statistically significant lower birth weight and greater rate of spontaneous abortion in the topiramate treated group. The small number of patients on topiramate and the lack of strict controls, unfortunately, mean that the study of Ornoy et al. suffers even more from statistical limitations than other studies.
Statistical limitations aside, the overall rate of MCM attributed to topiramate is similar to the rate reported for most other AEDs that have been investigated in pregnancy registries. The essential results are listed in the Table 1 and previously have been reviewed in detail (1). The risk reported for lamotrigine (1.4-3.2%) is very low overall but may be increased for oral clefts, although a different approach suggests no increased risk (3). The risk of levetiracetam is 2.7% from the same UK registry that reports here the risk of 4.8% for topiramate; however, much larger numbers of patients will have to be investigated to determine if the risk of topiramate is really greater than levetiracetam. The risk for carbamazepine (2.2-4.0%) is comparable to topiramate and other second-generation drugs investigated so far. There is a trend toward higher risk for conventional AEDs because of the higher numerical risk associated with phenytoin (5.9%) and phenobarbital (6.5%) than with topiramate.
It is very clear that the teratogenic risk for valproate (6.2-10.7%) is higher than for topiramate and all other AEDs reported so far (4). The risk of valproate was as high as 38.5% for doses greater than 1,100 mg per day in the Australian registry. Furthermore, valproate is associated with neural tube defects, which generally are more debilitating than cleft lip and palate associated with other AEDs. Valproate stands out as the one AED that should be avoided during pregnancy, when alternatives are available.
Is the rate of MCM significantly higher in women with epilepsy than in the general population? Birth defects occur in 1.6 to 2.3 percent of all live births (5, 6) . With the exception of valproate, the MCM rate for women with epilepsy taking AEDs is about twice the background rate, as a generality. This finding may cause women to be concerned. However, the absolute risk is still less than 4% for most AEDs. Therefore, women can be reassured that the vast majority of pregnancies turn out normal for women with epilepsy. However, it is certainly prudent to take measures aimed at minimizing the risk of birth defects, especially by recommending the use of prenatal folic acid and proper obstetric care.
What is the clinical significance of the findings reported by Hunt et al. and the pregnancy registry results reviewed here? On one hand, both clinicians and patients can be reassured that the results of systematic research confirm the clinical impression that most AEDs, other than valproate, have a low risk of anatomic teratogenicity. On the other hand, this fact does not address the risk of more subtle or delayed cognitive effects of intrauterine exposure to AEDs. Overall, recommendations typically are to continue AED treatment for pregnant women with epilepsy, avoid valproate, and hope that second-generation AEDs have relatively lower teratogenicity. 
C onvulsive status epilepticus (SE), continuous or recurrent epileptic seizures without full recovery between seizures, is a neurological emergency requiring rapid diagnosis and treatment to prevent morbidity and mortality. Since early treatment is more efficacious, the duration of seizures required to diagnose SE has been progressively shortened, from 30 to 10 or even 5 minutes (1). In adults, intravenous lorazepam has been identified as the most effective initial treatment but controls SE only two-thirds of the time (2, 3) . Treatment for SE in children has been less well studied than in adults. A recent Cochrane review of four studies of prolonged convulsive seizures in children concluded that 1) intravenous lorazepam is at least as effective as intravenous diazepam and is associated with fewer adverse events, and 2) buccal midazolam is the treatment of choice when intravenous access is not available (4) . In a randomized, controlled, unblinded study of prolonged seizures among patients in the United Kingdom, buccal midazolam stopped seizures within 10 minutes and prevented recurrence in the next hour in 56 percent of subjects, compared with 27 percent for rectal diazepam (5) . Respiratory depression (i.e., a fall in oxygen saturation or decrease in respiratory rate necessitating assisted breathing with face-mask inflation or intubation) was seen in approximately 5.5 percent of patients in both groups.
Should SE treatment be the same in developed and developing countries, which have markedly different etiologies of SE? In developed countries, febrile seizures and low antiepileptic drug (AED) levels cause most cases of SE in children. In developing countries, acute symptomatic etiologies, most often CNS infections, account for 28 to 67 percent of cases of SE (6) . In malaria-endemic areas, falciparum malaria is the leading 
